Health Technology · Pharmaceuticals: Major · NSE: AARTIPHARM · data 2026-10-09
Aarti Pharmalabs Limited
Health check: Average (5.7/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹855.5
Market cap
₹7,974 cr
P/E
36.4
P/B
—
ROE
8.5%
ROCE
11.5%
Debt / equity
0.36
Dividend yield
0.40%
1-year return
2.1%
52-week high
₹1,002.4
52-week low
₹585
Operating margin
16.7%
Growth
| Revenue (last 12 months) | ₹1,969 cr |
| Net profit (last 12 months) | ₹213 cr |
| Sales growth, 3 years (yearly) | -2.6% |
| Profit growth, 3 years (yearly) | -3.3% |
Similar companies
Procter & Gamble Health Ltd. (PGHL) · Sanofi Consumer Healthcare India Limited (SANOFICONR) · Suven Life Sciences Limited (SUVEN) · Morepen Laboratories Limited (MOREPENLAB) · Bliss GVS Pharma Limited (BLISSGVS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AARTIPHARM in NSE Scanner →